Last reviewed · How we verify
HEC110114
At a glance
| Generic name | HEC110114 |
|---|---|
| Sponsor | Sunshine Lake Pharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C (PHASE2, PHASE3)
- Pharmacokinetics of Midazolam When Co-administered With HEC74647 and HEC110114 (PHASE1)
- Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects (PHASE1)
- The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects (PHASE1, PHASE2)
- The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HEC110114 CI brief — competitive landscape report
- HEC110114 updates RSS · CI watch RSS
- Sunshine Lake Pharma Co., Ltd. portfolio CI